EUVIMEDEUVIMED entdecken
Crossref

Therapeutic potential of retinoic acid-loaded lipid Nanocapsules in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis

Rui Pedro Moura, Ariane Mwema, Pauline Bottemanne, Bernard Ucakar, Kevin Vanvarenberg, Ana Paula Pêgo, Giulio G Muccioli, Bruno Sarmento, Anne des Rieux

Journal of Controlled Release · 2026-05 · 393 · 114804

DOI: 10.1016/j.jconrel.2026.114804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-05. Verfasst von Rui Pedro Moura und 8 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal; INEB - Instituto de Enge…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Tretinoin, Multiple Sclerosis, Nanocapsules. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia, Charcot Foundation, Fund for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic neuroinflammatory disease affecting over 2.5 million people worldwide. Despite available therapies, no current treatment halts disease progression or specifically targets remyelination. Here, we evaluated for the first time the early therapeutic potential of retinoic acid-loaded lipid nanocapsules (LNC RA in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. We first compared intravenous and intranasal administration routes. While transferrin-receptor binding peptide (TfRp)-LNC demonstrated enhanced permeability across an in vitro nasal epithelium model compared to free RA, this did not translate in vivo. TfRp functionalization failed to improve brain accumulation and was associated with systemic toxicity. Based on these findings, unmodified LNC RA administered intravenously was selected for therapeutic evaluation in EAE mice. In an early treatment protocol, LNC RA significantly reduced disease severity in EAE mice. Demyelination was attenuated, with a 2.5-fold reduction in fluoromyelin-negative area in spinal cord tissue. No significant modulation of inflammatory markers was observed. These results highlight LNC RA as a promising platform for the treatment of neuroinflammatory diseases. Further studies will optimize CNS targeting and explore combination strategies with immunomodulatory or pro-remyelinating agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalTretinoinMultiple SclerosisNanocapsulesAnimalsFemaleMice, Inbred C57BLLipidsSpinal CordBrainReceptors, TransferrinMice

Stichwörter der Autor:innen

NanomedicinesNeuroinflammationRemyelinationTargeting peptideTransferrin receptor targeting

Substanzen

TretinoinNanocapsulesLipidsReceptors, Transferrin

Autor:innen und Institutionen

  • i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal; INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, 4200-1…
  • Université Catholique de Louvain, UCLouvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue E. Mounier 73, 1200 Brussels, Belgium; Université Catholique de Louvain, UCLouvain, Louvain D…
  • Université Catholique de Louvain, UCLouvain, Louvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids, Avenue E. Mounier 72, 1200 Brussels, Belgium.
  • Université Catholique de Louvain, UCLouvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue E. Mounier 73, 1200 Brussels, Belgium.
  • Université Catholique de Louvain, UCLouvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue E. Mounier 73, 1200 Brussels, Belgium. Electronic address: anne.desrieux@uclouvain.be.

Förderung

  • Fundação para a Ciência e a Tecnologia
  • Charcot Foundation
  • Fund for Scientific Research
  • Universidade do Porto

Zitieren

APA

Moura, R. P., Mwema, A., Bottemanne, P., Ucakar, B., Vanvarenberg, K., Pêgo, A. P., Muccioli, G. G., Sarmento, B., & des Rieux, A. (2026). Therapeutic potential of retinoic acid-loaded lipid Nanocapsules in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Journal of Controlled Release, 393, 114804. https://doi.org/10.1016/j.jconrel.2026.114804

Vancouver

Moura RP, Mwema A, Bottemanne P, Ucakar B, Vanvarenberg K, Pêgo AP, et al. Therapeutic potential of retinoic acid-loaded lipid Nanocapsules in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Journal of Controlled Release. 2026;393:114804. doi:10.1016/j.jconrel.2026.114804

BibTeX
@article{Moura2026,
  author = {Moura, Rui Pedro and Mwema, Ariane and Bottemanne, Pauline and Ucakar, Bernard and Vanvarenberg, Kevin and Pêgo, Ana Paula and Muccioli, Giulio G and Sarmento, Bruno and des Rieux, Anne},
  title = {Therapeutic potential of retinoic acid-loaded lipid Nanocapsules in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {393},
  pages = {114804},
  doi = {10.1016/j.jconrel.2026.114804}
}
Kostenlos starten →